Publication

Indirect Impact of Ten-valent Pneumococcal Conjugate Vaccine Program on Reducing Antimicrobial Use and Tympanostomy Tube Placements in Finland

Authored by:

Palmu, A. A., Rinta-Kokko, H., Nohynek, H., & Nuorti, J. P.

Full Citation:

Palmu, A. A., Rinta-Kokko, H., Nohynek, H., & Nuorti, J. P. 2019. Indirect Impact of Ten-valent Pneumococcal Conjugate Vaccine Program on Reducing Antimicrobial Use and Tympanostomy Tube Placements in Finland. The Pediatric Infectious Disease Journal. 39(9).

View Publication

Additional key concepts from this publication:

The pneumococcal conjugate vaccine has been shown to significantly reduce the rate of antibiotic and multi-drug resistant strains of pneumococcal disease.

The 2010 introduction of PCV10 for infants in Finland led to an estimated 15% reduction among unvaccinated children in purchases of antimicrobials recommended for acute otitis media (AOM), the most common reason for antimicrobial use in many countries. The indirect effects of PCV10 introduction contribute to health care savings and may also help to combat antimicrobial resistance.